Business
OXB notes interim results from AZ on AZD1222
OXB notes interim results from AZ on AZD1222.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \n \n RNS Number : 5342T\n Oxford Biomedica PLC\n 20 July 2020\n \n \n \n \n Oxford Biomedica notes interim results from AstraZeneca on AZD1222 showing strong antibody and T-cell responses and acceptable safety profile\n \n \n \n \n \n \n Oxford, UK - 20 July, 2020:\n \n Oxford Biomedica plc (LSE:OXB) (\"Oxford Biomedica\" or \"the Group\"), a leading gene and cell therapy group, notes that AstraZeneca UK Ltd (\"AstraZeneca\") has announced interim results from the ongoing Phase I/II COV001 trial, led by Oxford University on AZD1222 which showed the SARS-CoV-2 vaccine candidate AZD1222 was tolerated and generated robust immune responses against the SARS-CoV-2 virus in all evaluated participants.\n \n \n COV001 is a blinded, multi-centre, randomised controlled Phase I/II trial with 1,077 healthy adult participants, aged 18-55 years. It assessed a single dose of AZD1222 against a comparator meningococcal conjugate vaccine, MenACWY. Ten participants also received two doses of AZD1222 one month apart.\n \n \n The results published in \n \n The Lancet\n \n confirmed a single dose of AZD1222 resulted in a four-fold increase in antibodies to the SARS-CoV-2 virus spike protein in 95% of participants one month after injection. In all participants, a T-cell response was induced, peaking by day 14, and maintained two months after injection.\n \n \n Neutralising activity against SARS-CoV-2 (as assessed by the MNA80 assay) was seen in 91% of participants one month after vaccination and in 100% of participants who received a second dose. The levels of neutralising antibodies seen in participants receiving either one or two doses were in a similar range to those seen in convalescent COVID-19 patients. Strong correlations were observed across neutralisation assays.\n \n \n To view the full announcement from AstraZeneca please follow this \n \n link\n \n \n \n As announced on 28 May 2020, Oxford Biomedica has signed a one year Clinical & Commercial Supply Agreement with AstraZeneca who will have access to Oxford Biomedica's new 7,800 m2 commercial manufacturing centre Oxbox, located in Oxford, UK. The initial agreement requires Oxford Biomedica to provide AstraZeneca with multiple batches of vaccine, the majority of which are expected to be produced throughout 2020. The production will be from one of the Group's recently...